B.H. Wolffenbuttel
Dept. of Endocrinology & Metabolism
University Hospital Maastricht
P.O. Box 5800
NL-6202 AZ Maastricht
Netherlands
Name/email consistency: high
- Rosiglitazone. Wolffenbuttel, B.H., Sels, J.P., Huijberts, M.S. Expert. Opin. Pharmacother (2001)
- Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Wolffenbuttel, B.H., Gomis, R., Squatrito, S., Jones, N.P., Patwardhan, R.N. Diabet. Med. (2000)
- Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Wolffenbuttel, B.H., Sels, J.P., Rondas-Colbers, G.J., Menheere, P.P. Neth. J. Med (1999)
- A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Wolffenbuttel, B.H., Landgraf, R. Diabetes. Care (1999)
- Repaglinide--a new compound for the treatment of patients with type 2 diabetes. Wolffenbuttel, B.H. Neth. J. Med (1999)
- Beneficial gamma-knife radiosurgery in a patient with Nelson's syndrome. Wolffenbuttel, B.H., Kitz, K., Beuls, E.M. Clin. Neurol. Neurosurg (1998)
- Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Wolffenbuttel, B.H., Mahla, G., Muller, D., Pentrup, A., Black, D.M. Neth. J. Med (1998)
- Comparison of different insulin regimens in elderly patients with NIDDM. Wolffenbuttel, B.H., Sels, J.P., Rondas-Colbers, G.J., Menheere, P.P., Nieuwenhuijzen Kruseman, A.C. Diabetes. Care (1996)